1
|
Santoro F, Dasgupta S, Schnitker J, Auth T, Neumann E, Panaitov G, Gompper G, Offenhäusser A. Interfacing electrogenic cells with 3D nanoelectrodes: position, shape, and size matter. ACS NANO 2014; 8:6713-23. [PMID: 24963873 DOI: 10.1021/nn500393p] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/18/2023]
Abstract
An in-depth understanding of the interface between cells and nanostructures is one of the key challenges for coupling electrically excitable cells and electronic devices. Recently, various 3D nanostructures have been introduced to stimulate and record electrical signals emanating from inside of the cell. Even though such approaches are highly sensitive and scalable, it remains an open question how cells couple to 3D structures, in particular how the engulfment-like processes of nanostructures work. Here, we present a profound study of the cell interface with two widely used nanostructure types, cylindrical pillars with and without a cap. While basic functionality was shown for these approaches before, a systematic investigation linking experimental data with membrane properties was not presented so far. The combination of electron microscopy investigations with a theoretical membrane deformation model allows us to predict the optimal shape and dimensions of 3D nanostructures for cell-chip coupling.
Collapse
Affiliation(s)
- Francesca Santoro
- Institute of Bioelectronics (ICS-8/PGI-8) and ‡Institute of Theoretical Soft Matter and Biophysics (ICS-2/IAS-2), Forschungszentrum Jülich , 52428 Jülich, Germany
| | | | | | | | | | | | | | | |
Collapse
|
2
|
Gulizia M, Mangiameli S, Orazi S, Chiarandà G, Boriani G, Piccione G, DiGiovanni N, Colletti A, Puntrello C, Butera G, Vasco C, Vaccaro I, Scardace G, Grammatico A. Randomized comparison between Ramp and Burst+ atrial antitachycardia pacing therapies in patients suffering from sinus node disease and atrial fibrillation and implanted with a DDDRP device. ACTA ACUST UNITED AC 2006; 8:465-73. [PMID: 16798758 DOI: 10.1093/europace/eul055] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
AIMS Atrial tachycardia and flutter frequently occur in association with atrial fibrillation and may be treated by overdrive pacing in patients who receive pacemakers with antitachycardia pacing (ATP) capabilities. The PITAGORA trial was a multi-centre, randomized, cross-over study aimed at comparing two different ATP modes for atrial tachyarrhythmia (AT) termination in patients suffering from sinus node disease (SND). METHODS AND RESULTS One hundred and seventy-six patients (72 M, age 71+/-9 years) received a Medtronic AT500 pacemaker. All patients were on class IC or III antiarrhythmic drugs. After a 5-month observation period, 170 patients were randomized to either Ramp or Burst+ ATP therapy; 4 months later they crossed over. One hundred and fifty-seven patients completed the 13 months of follow-up; 114 (72.6%) suffered 6088 AT episodes. In 75 patients, 1904 AT episodes were treated and 934 (49.1%) successfully terminated. The median value of individual patients' ATP efficacy was 60%. Burst+ terminated 387 out of 873 AT episodes (44%) in 58 patients. Ramp terminated 547 out of 1031 AT episodes (53%, P<0.001) in 56 patients. Ramp efficacy was significantly (P<0.01) and directly correlated with AT cycle length (ATCL), whereas Burst+ efficacy was not. Ramp showed higher (P<0.001) termination efficacy than Burst+ for ATCL >240 ms. Quality of life, as measured by the EuroQoL questionnaire, and number of symptoms significantly improved in the overall population. This improvement was significantly higher in patients with ATP efficacy >60%. CONCLUSION In patients suffering from SND and AT, Ramp therapy shows higher termination efficacy than Burst+ therapy in AT episodes with ATCL >240 ms. Further studies are required to show the impact of ATP on clinical outcomes.
Collapse
Affiliation(s)
- Michele Gulizia
- Cardiology Department, Garibaldi-Nesima Hospital, Via Palermo 636, Catania 95122, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Estes NA, Haugh CJ, Wang PJ, Manolis AS. Antitachycardia pacing and low-energy cardioversion for ventricular tachycardia termination: a clinical perspective. Am Heart J 1994; 127:1038-46. [PMID: 8160578 DOI: 10.1016/0002-8703(94)90084-1] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
When incorporated into tiered therapy implantable cardioverter defibrillators (ICDs), antitachycardia pacing (ATP) techniques have proved useful for termination of sustained monomorphic ventricular tachycardias (VT) and have the advantages of rapid delivery, absence of patient discomfort, and minimal battery drain. The efficacy of low-energy cardioversion (LEC) is similar to that of pacing techniques for VT termination, but LEC has the disadvantages of patient discomfort, atrial proarrhythmia, and greater battery drain compared with ATP. Acceleration of VT occurs with similar frequency with each technique. Neither technique should be used without back-up defibrillation capability in an ICD. VT termination algorithms are currently empiric and require repetitive arrhythmia induction and trials of ATP or LEC. Future studies of the risk and benefits of each technique are likely to define optimal programming strategies in tiered therapy ICDs.
Collapse
Affiliation(s)
- N A Estes
- Cardiac Arrhythmia Service, New England Medical Center Hospital, Boston, MA 02111
| | | | | | | |
Collapse
|
4
|
Kojima R. The status of pacemaker implantations in Japan. Artif Organs 1994; 18:100-2. [PMID: 8141650 DOI: 10.1111/j.1525-1594.1994.tb03303.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
It has been over 40 years since the initial clinical application of a cardiac pacemaker. Currently, approximately 300 per million patients in the United States and Europe are kept alive owing to the benefit of implantable pacemakers. Recently, the Japanese Cardiac Pacing Society and the Japanese Society of Artificial Organs performed pacemaker registry studies for 1989 and 1990. In this paper, results of this survey are described. Currently, implantable cardiac pacemakers are utilized only on the level of 120 per million patients in Japan. Surprisingly, all implantations were performed using foreign manufactured pacemakers. Despite the high level of electronic technologies available in Japan, no Japanese-made implantable cardiac pacemakers are utilized in Japan. One could speculate that a major reason for the low level of clinical application of cardiac pacemakers is that these devices are quite expensive because of the import duties imposed on them. It is necessary and strongly recommended that implantable cardiac pacemakers be manufactured in Japan in order for them to be utilized as fully as they are in the United States and Europe.
Collapse
Affiliation(s)
- R Kojima
- Department of Surgery, Baylor College of Medicine, Houston, TX 77030
| |
Collapse
|
5
|
Turner TR, Thomson PJ, Cameron MA. Statistical discriminant analysis of arrhythmias using intracardial electrograms. IEEE Trans Biomed Eng 1993; 40:985-9. [PMID: 8288290 DOI: 10.1109/10.245621] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The problem of classifying ventricular arrhythmias from intracardial electrograms is considered. Standard statistical discrimination procedures are applied using a simple parametric model for the shape of the pulse near its peak. This approach makes simultaneous use of the model parameters, has well known statistical properties, and involves computations that can be carried out efficiently. Preliminary analyses of real data sets, using both linear and quadratic discrimination functions, yield promising results.
Collapse
Affiliation(s)
- T R Turner
- Department of Mathematics and Statistics, University of New Brunswick, Fredericton, Canada
| | | | | |
Collapse
|
6
|
Newman D, Dorian P, Hardy J. Randomized controlled comparison of antitachycardia pacing algorithms for termination of ventricular tachycardia. J Am Coll Cardiol 1993; 21:1413-8. [PMID: 8473650 DOI: 10.1016/0735-1097(93)90318-u] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
OBJECTIVES This study compared the efficacy and safety of two antitachycardia pacing algorithms in the treatment of ventricular tachycardia. BACKGROUND There is agreement that antitachycardia pacing should be adapted to tachycardia rate and be delivered in a burst, but the ideal pacing pattern is not well understood. Effective antitachycardia pacing burst patterns include those with a between-burst decrement (SCAN) with or without an additional within-burst decrement (RAMP). METHODS Prospective randomized crossover comparison of two antitachycardia pacing algorithms (RAMP vs. SCAN) on identical induced sustained ventricular tachycardias was performed. RESULTS Sixty-five ventricular tachycardias (mean cycle length 364 +/- 74 ms) from 37 invasive studies performed in 29 patients were studied; 86% of patients had coronary artery disease and 72% were receiving antiarrhythmic therapy at the time of study. Of the 65 tachycardias, 40 were identical pairs and 25 were unpaired (including 8 with a > 30-ms difference in cycle length of induced ventricular tachycardia pairs). In the paired pacing trials, conversion to sinus rhythm occurred, respectively, in 85% of SCAN versus 90% of RAMP protocols (p = 0.63, power = 93%) and within 1.4 +/- 0.7 versus 1.7 +/- 1.1 attempts (p = 0.41). Discordance for pacing success was seen in three pairs. In unpaired trials, conversion to sinus rhythm occurred in 73% and 57%, respectively (p = 0.68, power = 88%). Tachycardia acceleration during pacing occurred in 7 (11%) of 65 attempts (5 SCAN, 2 RAMP). Acceleration in unpaired ventricular tachycardia trials was correlated with tachycardia cycle length. Failure to convert ventricular tachycardia was associated with a shorter tachycardia cycle length (p < 0.05). CONCLUSIONS In the patients studied, adaptive antitachycardia pacing was safe and effective and, when successful, occurred within three attempts of an 8-beat adaptive burst algorithm. Changes in burst pattern did not affect pacing safety or efficacy. Antitachycardia pacing success was dependent on induced ventricular tachycardia cycle length.
Collapse
Affiliation(s)
- D Newman
- Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada
| | | | | |
Collapse
|
7
|
Griffith MJ, Bexton RS, McComb JM. Financial audit of antitachycardia pacing for the control of recurrent supraventricular tachycardia. Heart 1993; 69:272-5. [PMID: 8461232 PMCID: PMC1024997 DOI: 10.1136/hrt.69.3.272] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
OBJECTIVE To assess the financial implications of antitachycardia pacing in patients with frequent supraventricular tachycardia. PATIENTS Intertach pacemakers were implanted in 25 patients (mean age 47 years, five men): 22 had atrioventricular nodal reentry tachycardia. The patients had failed a mean of 4.9 (range zero to eight) drugs and had been admitted to hospital 3.7 (zero to 31) times over a symptomatic period of 13.9 years (two months to 54 years). RESULTS The mean admission time for implantation was 2.8 (two to seven) days. One patient with Wolff-Parkinson-White syndrome subsequently underwent surgery. Infection occurred in two patients, and pain over the pacemaker required its resiting in two. Two patients have had one admission each for tachycardia. Six patients remain on anti-arrhythmic drugs. Costs were calculated including value added tax, capital charges, and allocated overheads. The cost a year before pacing was 1174 pounds including drug costs, clinic visits, and hospital admissions. The mean cost of pacemaker implantation was 3364.22 pounds, including the pacemaker and lead, admission and procedure, readmissions and first pacing check. Subsequent annual follow up cost was 73.72 pounds including annual clinic visits and drug costs. The cost of pacing is 4241 pounds whereas medical management costs 7044 pounds assuming pacemaker life of six years: with a 10 year life the cost is 4537 pounds compared with 11,740 pounds: with a 12 year life the cost is 4685 pounds compared with 14,088 pounds. CONCLUSION The excess cost of implantation of an antitachycardia pacemaker is minimal in patients with frequent supraventricular tachycardia despite drug treatment and is justified by excellent control of symptoms and reduction of drug use and hospital admissions.
Collapse
Affiliation(s)
- M J Griffith
- Cardiac Department, Freeman Hospital, Newcastle upon Tyne
| | | | | |
Collapse
|
8
|
|
9
|
Bardy GH, Troutman C, Poole JE, Kudenchuk PJ, Dolack GL, Johnson G, Hofer B. Clinical experience with a tiered-therapy, multiprogrammable antiarrhythmia device. Circulation 1992; 85:1689-98. [PMID: 1572027 DOI: 10.1161/01.cir.85.5.1689] [Citation(s) in RCA: 121] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
BACKGROUND The purpose of this report is to describe our initial experience with a tiered-therapy, variable detection criteria, multiprogrammable antiarrhythmia device capable of antitachycardia pacing, cardioversion, and defibrillation in 50 cardiac arrest survivors. METHODS AND RESULTS An epicardial lead system was used in 35 patients. A transvenous lead system was used in 15 patients. The index arrhythmia leading to device implantation was ventricular fibrillation (VF) in 23 patients, ventricular tachycardia (VT) in 21 patients, and both VT and VF in six patients. Postoperatively, all 50 patients benefited from the additional functions available in the new device compared with a device capable only of high-energy termination of arrhythmias using a simple rate detection algorithm. Total patient survival over a mean follow-up period of 15 +/- 5 months was 96%, with no patient succumbing to sudden arrhythmic death, cardiac death, or surgical death. Nine patients (18%) avoided the need for a bradycardia pacemaker because of the device's backup bradycardia pacing function. A programmable tachycardia cycle length stability algorithm prevented inappropriate device intervention into atrial fibrillation in 11 patients (22%). Detection schema flexibility, antitachycardia pacing capabilities, and low-energy cardioversion options allowed the elimination or avoidance of antiarrhythmic drugs in 41 patients (82%). Device data storage facilitated troubleshooting and reprogramming of detection algorithms and therapeutic schema in all 50 patients. Finally, the ability to perform noninvasive programmed electrical stimulation obviated the need for invasive cardiac catheterization in 35 of 35 patients who required electrophysiological testing after device implantation. CONCLUSIONS These findings indicate that a multiprogrammable antiarrhythmia device can provide a substantial advance in the treatment of patients with disabling or life-threatening ventricular arrhythmias by minimizing the use of painful shocks, reducing the need for antiarrhythmic drugs, lowering the incidence of inappropriate shocks, facilitating electrophysiological evaluation, and obviating the need for dual-device therapy.
Collapse
Affiliation(s)
- G H Bardy
- Department of Medicine, University of Washington, Seattle
| | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
Our review of the current literature and experience in caring for pacemaker patients suggests that a consideration of hemodynamics is a logical way to approach pacemaker selection and programming. Multiple clinical factors enter into the selection of a pacemaker or pacemaker programming settings in each case. It appears that in patients with sinus node disease, atrial-inhibited or dual-chamber pacing provides the best chance for preventing the development of chronic atrial fibrillation with its attendant risks of embolism and stroke. It is clear that AV synchrony has beneficial hemodynamic effects at rest in most patients. The results of Labovitz would suggest that in patients with marked left atrial enlargement, this may be less so. The results of Stewart et al would further suggest that in patients with retrograde VA conduction, dual-chamber pacing is preferable. Retrograde VA conduction can be intermittent and this makes it difficult to use its absence on a single test to decide on the type of pacemaker to use. It appears that baseline left ventricular function does not determine the relative improvement in cardiac output observed with AV synchrony or rate-adaptive pacing. However, in patients with severe congestive heart failure even a small improvement in cardiac output may result in significant clinical improvement. Studies have shown that in any given patient, there may be an optimal AV interval at rest. In general, this ranges from 100 to 150 milliseconds. In normal individuals the optimal AV interval shortens with increased heart rate during exercise in a predictable and linear fashion. The hemodynamic benefits of a shortened AV interval with faster heart rates in pacemaker patients have not yet been shown. Intuitively, however, this would appear to be a desirable approach and will probably be added to the design of future generations of dual-chamber pacemakers. Studies of the effect of different pacing modes on secretion of atrial natriuretic factor are intriguing and may contribute more to our understanding of pacing hemodynamics in the future. During exercise, heart rate increase is more important than AV synchrony and this has been shown by several studies. Thus, in active patients with chronotropic incompetence due to sick sinus syndrome, the addition of rate-adaptive pacing is important. Because single-chamber rate-adaptive atrial pacing leaves the patient exposed to the risk of future development of AV block and DDD pacing does not provide chronotropic support, it is likely that the new rate-adaptive dual-chamber (DDDR) devices will be used in a significant number of these patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
|
11
|
Gertsch M, Hottinger S, Hess T. Serial chest thumps for the treatment of ventricular tachycardia in patients with coronary artery disease. Clin Cardiol 1992; 15:181-8. [PMID: 1551266 DOI: 10.1002/clc.4960150309] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Based on excellent results of successive single chest thumping (CT) and serial chest thumping (SCT) for the interruption of ventricular tachycardia (VT) in experimental animals with subacute myocardial infarction, the SCT method was applied for the treatment of VT in patients with coronary artery disease (CAD). SCT was successful in terminating 13 of 19 episodes of VT (68%) in 8 of 14 patients (57%). Conversion of VT was immediate in 9 episodes in 6 patients and latent in 4 episodes in 2 patients. Complications were rare but significant. In one case, SCT resulted in a ventricular asystole and in another case SCT accelerated the rate of VT from 167/min to 242/min, requiring electroconversion. Neither a short duration of VT nor a preserved left ventricular function seemed to enhance conversion by SCT. For interruption of VT in patients with CAD, SCT is not as successful as in the experimental animal model and, therefore, should not be used as a routine method. It may be applied in selected patients under hospital conditions with a standby defibrillator.
Collapse
Affiliation(s)
- M Gertsch
- Department of Cardiology, Medical University Clinic, Inselspital Bern, Switzerland
| | | | | |
Collapse
|
12
|
Jung W, Mletzko R, Manz M, Lüderitz B. Long-Term Therapy of Antitachycardia Pacing for Supraventricular Tachycardia. PACING AND CLINICAL ELECTROPHYSIOLOGY: PACE 1992; 15:179-87. [PMID: 1372417 DOI: 10.1111/j.1540-8159.1992.tb03062.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Long-term antitachycardia pacing therapy with the InterTach 262-12 and 262-16 was evaluated in 32 consecutive patients (mean age 50 +/- 13 years) with recurrent, drug refractory supraventricular tachycardia. AV nodal reentrant tachycardia was present in 20 patients, Wolff-Parkinson-White syndrome in ten patients, and a reentrant tachycardia due to Mahaim fibers in one patient. During follow-up of 39 +/- 17 months, 250 persistent tachycardia episodes occurred in 22 patients. By adjusting detection and termination mode, recurrent supraventricular tachycardia could be controlled in 19 of 32 patients (60%) by antitachycardia pacing alone. Concomitant antiarrhythmic drug therapy was required in ten of 32 patients (30%). During follow-up antitachycardia pacing became ineffective in three patients (10%). Thus, chronic antitachycardia pacing proved to be safe and effective in selected patients with drug refractory supraventricular tachycardia and could significantly improve quality of life by rapid termination of recurrent supraventricular tachycardia episodes.
Collapse
Affiliation(s)
- W Jung
- Department of Cardiology, University of Bonn, Germany
| | | | | | | |
Collapse
|
13
|
Abstract
Nonpharmacologic therapy for ventricular arrhythmias has gained growing attention with the development of the implantable cardioverter-defibrillator. In addition, the reports of adverse effects of drug therapy from several studies, including the Cardiac Arrhythmia Suppression Trial (CAST), have supported the need for these devices. The development of new implantable cardioverter-defibrillators that have the capability of antitachycardia pacing, bradycardia pacing, cardioversion and defibrillation has enhanced their clinical utility. The currently available implantable cardioverter-defibrillators have been shown to significantly improve survival after sudden cardiac arrest in patients with life-threatening ventricular arrhythmias. Newer devices with expanded capabilities may reduce mortality even further. In this report the features of currently available antitachycardia devices and implantable cardioverter-defibrillators are reviewed and the features and current implant data on newer antitachycardia devices are discussed.
Collapse
Affiliation(s)
- L S Klein
- Krannert Institute of Cardiology, Indianapolis, Indiana 46202-4800
| | | | | |
Collapse
|
14
|
Malik M, Camm AJ. Computer simulation of overdrive pacing during atrioventricular reentrant tachycardia. INTERNATIONAL JOURNAL OF BIO-MEDICAL COMPUTING 1991; 29:7-21. [PMID: 1959984 DOI: 10.1016/0020-7101(91)90009-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The study used a computer model of cardiac excitation to reproduce atrioventricular (AV) reentrant tachycardia and to evaluate the possibility of its termination by overdrive burst pacing. The model simulated activation waves radiating along a one-dimensional circular pathway, the portions of which represented the atrial, AV nodal, His-Purkinje, ventricular, and bypass parts of the tachycardia circuit. The pathway consisted of 289 elements. Only depolarised and resting states of elements were modelled. Differential refractoriness and conduction velocity for each element and the cycle length dependence of AV nodal decremental conduction were introduced. The experiments with the model examined the ability of overdrive 'on-circuit' pacing to terminate the tachycardia in order to determine the relevance of: (a) the coupling interval of the first beat in the burst; (b) the cycle length of the burst; (c) the number of stimuli in the burst; (d) His-Purkinje refractoriness; and (e) the degree of AV nodal decremental conduction. The results suggested that: (A) the general impression of a regular recovery wave and of a regular excitable window moving uniformly along the macro-reentrant circular path is incorrect; (B) the use of overdrive bursts of several stimuli with a short coupling interval has unpredictable effects; (C) the use of faster bursts with a cycle length only slightly shorter than the tachycardia cycle length is more safe (with respect to tachycardia reinitiation) and for certain combinations of the coupling interval and cycle length, prolonged bursts do not reinitiate the tachycardia; (D) the likelihood of tachycardia termination is increased by prolonging the refractoriness of the tachycardia circuit and by reducing AV nodal decremental conduction.
Collapse
Affiliation(s)
- M Malik
- Department of Cardiological Sciences, St. George's Hospital Medical School, London, U.K
| | | |
Collapse
|
15
|
Bonnet CA, Fogoros RN, Elson JJ, Fiedler SB, Burkholder JA. Long-term efficacy of an antitachycardia pacemaker and implantable defibrillator combination. Pacing Clin Electrophysiol 1991; 14:814-22. [PMID: 1712959 DOI: 10.1111/j.1540-8159.1991.tb04112.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Antitachycardia pacemakers and implantable cardioverter defibrillators (ICD) were implanted in 14 patients to control recurrent hemodynamically stable ventricular tachycardia (VT). All patients underwent extensive preimplant testing in the electrophysiology laboratory documenting that in each patient at least 50 episodes of VT could be reliably terminated by an external model of the antitachycardia pacemaker. The burst scanning mode of antitachycardia pacing was used in all patients. ICDs were implanted solely as a back up should acceleration of VT occur, and all had high nonprogrammable rate cutoffs (mean 191 +/- 12 beats/min). During a mean follow-up of 25 +/- 6 months, 6,029 episodes of VT were treated in the 14 patients. Only 103 ICD discharges were required (approximately one discharge per 60 episodes of VT). Ten of the 14 patients received discharges from their ICDs. No deaths have occurred. All devices remain active and in the automatic mode. Thus, an antitachycardia pacemaker and ICD combination can safely and effectively terminate VT in highly selected patients who are subjected to extensive preimplant testing. In such patients, the vast majority of episodes of VT can be terminated with antitachycardia pacing, and only rarely is a discharge required from the ICD.
Collapse
Affiliation(s)
- C A Bonnet
- Division of Cardiology, Allegheny General Hospital, Medical College of Pennsylvania, Pittsburgh 15212
| | | | | | | | | |
Collapse
|
16
|
Fukushige J, Porter CB, Hayes DL, McGoon MD, Osborn MJ, Vlietstra RE. Antitachycardia pacemaker treatment of postoperative arrhythmias in pediatric patients. Pacing Clin Electrophysiol 1991; 14:546-56. [PMID: 1710060 DOI: 10.1111/j.1540-8159.1991.tb02827.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
An automatic antitachycardia pulse generator (Intertach 262-12) was implanted in each of six pediatric patients (mean age, 10 years) with drug-resistant and persistent postoperative supraventricular arrhythmias. Four had bradycardia-tachycardia syndrome, two after a Mustard procedure for transposition of the great arteries, one after a Senning procedure for the same anomaly, and one after a Fontan procedure for univentricular heart with transposition of the great arteries. Of the two remaining patients, one had atrial flutter after a modified Fontan procedure for univentricular heart and one had intra-atrial reentry tachycardia after a modified Fontan procedure for double-outlet right ventricle with pulmonary stenosis. During a mean follow-up interval of 31 months after implantation, pacemakers were activated on multiple occasions and functioned appropriately in all six patients. Complications necessitated six invasive interventions in three patients: erosion or infection of the system, adaptor fracture, and connector block fracture on one occasion each and lead dislodgment on three occasions. Four of the six patients continued to take drugs at the end of this study; however, all patients had their drug therapy reduced and one was taking digoxin only. The number of hospital admissions decreased after implantation. Despite a number of technical challenges, this newer multiprogrammable antitachycardia pacemaker appears to be a valuable addition to the treatment of refractory postoperative supraventricular tachyarrhythmias in pediatric patients.
Collapse
Affiliation(s)
- J Fukushige
- Section of Pediatric Cardiology, Mayo Clinic, Rochester, MN 55905
| | | | | | | | | | | |
Collapse
|
17
|
Kavanagh KM, Wyse DG, Duff HJ, Gillis AM, Sheldon RS, Mitchell LB. Drug therapy for ventricular tachyarrhythmias: how many electropharmacologic trials are appropriate? J Am Coll Cardiol 1991; 17:391-6. [PMID: 1991895 DOI: 10.1016/s0735-1097(10)80104-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
To determine how many electropharmacologic drug trials should be performed to select therapy for patients with ventricular tachyarrhythmias, the outcome of 150 consecutive patients with inducible ventricular tachyarrhythmias undergoing serial electropharmacologic testing was examined. The probability of identifying predicted effective therapy (inductive of fewer than five ventricular responses with three ventricular extrastimuli at three pacing cycle lengths) and the probability of that therapy preventing sustained ventricular tachyarrhythmia recurrences were determined as a function of the number of preceding trials. The probability ( +/- SE) of identifying predicted effective therapy by the first trial (0.23 +/- 0.03) was significantly higher than that of the second (0.09 +/- 0.04), third (0.08 +/- 0.04) and fourth (0.05 +/- 0.04) trials (p = 0.001). No patient had predicted effective therapy identified by subsequent trials. The 2 year actuarial probability of freedom from sustained ventricular tachyarrhythmias on predicted effective therapy was higher for the first (0.79 +/- 0.08), second (0.73 +/- 0.13) and third (0.86 +/- 0.13) trials than for the fourth (0.33 +/- 0.27) trial (p = 0.02). Thus, the probability of selecting therapy with long-term efficacy was highest for the first trial (0.18), intermediate for the second (0.07) and third (0.07) trials and lowest for the fourth (0.02) and subsequent (0.00) trials. Accordingly, the electropharmacologic approach to therapy selection should be abandoned after three unsuccessful trials.
Collapse
Affiliation(s)
- K M Kavanagh
- Department of Medicine, Foothills General Hospital, Calgary, Alberta, Canada
| | | | | | | | | | | |
Collapse
|
18
|
McComb JM, Jameson S, Bexton RS. Atrial antitachycardia pacing in patients with supraventricular tachycardia: clinical experience with the Intertach pacemaker. Pacing Clin Electrophysiol 1990; 13:1948-54. [PMID: 1704573 DOI: 10.1111/j.1540-8159.1990.tb06922.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
During a 3-year period, 22 patients with recurrent supraventricular tachycardia have been treated with antitachycardia pacemakers (Intermedics Intertach, 262-12, n = 17, and Intertach II, 262-16, n = 5). Eighty-two percent were female, the mean age was 44 +/- 14 years; 86% had atrioventricular node reentrant tachycardia. Symptoms had occurred over 11.8 +/- 7.1 years, with 3.6 hospital admissions per patient, despite 4.7 +/- 2.1 antiarrhythmic drugs. Following pacemaker implantation, during a follow-up of 14.8 +/- 11.5 months, only two patients have been readmitted to a hospital because of supraventricular tachycardia (mean 0.1 per patient). One patient is taking an antiarrhythmic agent, and four are taking beta adrenergic blocking agents. Thus, 23% are taking cardioactive drugs (it was anticipated that two patients would continue on drugs after pacemaker implantation). There have been no serious complications. Atrial antitachycardia is thus an effective therapy in carefully selected patients with recurrent supraventricular tachycardia, reducing hospital admissions for supraventricular tachycardia and reducing the need for antiarrhythmic drugs.
Collapse
Affiliation(s)
- J M McComb
- Regional Cardiothoracic Unit, Freeman Hospital, Newcastle upon Tyne, England, United Kingdom
| | | | | |
Collapse
|
19
|
|
20
|
den Dulk K, Brugada P, Smeets JL, Wellens HJ. Long-term antitachycardia pacing experience for supraventricular tachycardia. Pacing Clin Electrophysiol 1990; 13:1020-30. [PMID: 1697949 DOI: 10.1111/j.1540-8159.1990.tb02149.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
UNLABELLED A pacemaker was used to control drug-resistant reentrant supraventricular tachycardia (SVT) in 40 patients. An antitachycardia pacemaker was implanted in 37 for SVT; in one for ventricular tachycardia that could also be used to terminate SVT; in one SVT could be terminated with an activity rate variable pacemaker; and in one a DDD pacemaker was used for prevention and termination of SVT. Twenty patients had AV nodal reentrant tachycardias, eight had tachycardias due to a concealed accessory pathway, eight had a Wolff-Parkinson-White syndrome, three had reentrant atrial tachycardias, and one had atrial flutter. Twenty-two patients were paced from the right atrium, five from the coronary sinus, ten from the right ventricle, and three had a DDD pacemaker. During a total follow-up period of 1,503 (mean 38) months an estimated 16,240 episodes of tachycardia were terminated promptly at home, 58 required several attempts, 57 episodes lasted longer than 30 minutes but did not require medical attention, and 11 required hospital admission. Hospital admission for SVT decreased from one per patient-month (in the 3 months before implantation) to 1 per 137 patient-months after implantation. Additional reentrant tachycardias occurred in 13 patients. Antiarrhythmic drug therapy in combination with a conservative antitachycardia pacing mode was required in four patients paced from the atrium to avoid pacing induced atrial fibrillation. Antiarrhythmic drug therapy was used in 42% of patients to help control SVT. CONCLUSIONS (1) Drug-resistant SVTs can be safely and effectively managed on the long-term with antitachycardia pacemakers. (2) Rapid termination of SVT improved the quality-of-life significantly by avoiding prolonged episodes of tachycardia and repetitive hospital admissions.
Collapse
Affiliation(s)
- K den Dulk
- Department of Cardiology, Academic Hospital Maastricht, University of Limburg, The Netherlands
| | | | | | | |
Collapse
|
21
|
Deutsch N, Hantler CB, Morady F, Kirsh M. Perioperative management of the patient undergoing automatic internal cardioverter-defibrillator implantation. JOURNAL OF CARDIOTHORACIC ANESTHESIA 1990; 4:236-44. [PMID: 2131873 DOI: 10.1016/0888-6296(90)90245-b] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- N Deutsch
- Department of Anesthesiology, Medicine (Cardiology), University of Michigan School of Medicine, Ann Arbor
| | | | | | | |
Collapse
|
22
|
Mirowski M, Mower MM. Hemodynamic sensors for implantable defibrillators. J Am Coll Cardiol 1990; 15:656-7. [PMID: 2303635 DOI: 10.1016/0735-1097(90)90641-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
23
|
Silka MJ, Manwill JR, Kron J, McAnulty JH. Bradycardia-mediated tachyarrhythmias in congenital heart disease and responses to chronic pacing at physiologic rates. Am J Cardiol 1990; 65:488-93. [PMID: 2305688 DOI: 10.1016/0002-9149(90)90816-j] [Citation(s) in RCA: 66] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The coexistence of bradycardia and a tachyarrhythmia may preclude effective pharmacologic treatment of 1 arrhythmia without paradoxic aggravation of the other. This study evaluated the potential relation between the 2 types of arrhythmias and the effect of conventional modes and rates of pacing for bradycardia on the frequency of the associated tachyarrhythmias. Twenty-one young patients, aged 2 to 19 (mean 11) years with congenital heart disease and a tachyarrhythmia occurring in the setting of chronic bradycardia were studied. The effects of pacing were evaluated by comparison of the number of episodes of clinical tachycardia during the 12-month intervals before and after pacemaker implantation. During these intervals, antiarrhythmic drug therapy was not altered. Patients were analyzed as independent groups, based on the type of tachyarrhythmia: supraventricular (n = 5), atrial flutter (n = 9) and ventricular (n = 7). The modes of chronic pacing were AAI (n = 4), DDD (n = 6) and VVI (n = 11). The prevention of bradycardia by pacing was associated with a significant decrease in the frequency of supraventricular (p = 0.008) and ventricular (p = 0.02) tachyarrhythmias. However, the frequency of atrial flutter was not altered. Prevention of tachycardia was more frequently associated with the AAI and DDD modes of pacing compared to VVI (p = 0.08). Pacing represents an effective therapy for certain tachyarrhythmias associated with chronic bradycardia, although critical modes may be required.
Collapse
Affiliation(s)
- M J Silka
- Department of Pediatrics, Oregon Health Sciences University, Portland 97201
| | | | | | | |
Collapse
|
24
|
Affiliation(s)
- M A De Belder
- Department of Cardiological Sciences, St. George's Hospital Medical School, London, England
| | | | | | | |
Collapse
|
25
|
Abstract
Remarkable advances have been made over the last 2 decades in the management of tachyarrhythmias. Simultaneous developments have provided new drugs, new surgical and catheter ablation techniques and new implantable devices. Initial enthusiasm with antitachycardia pacemakers was tempered by the realization of dangers and difficulties associated with their use, particularly in the treatment of ventricular tachycardia. However, progress has been made along several lines: (1) improvements in the automatic detection of target tachyarrhythmias; (2) the development of termination algorithms that are more adaptable to spontaneous changes in the tachycardia termination zone; (3) improvements in the safety of termination algorithms; (4) development of automatic cardioversion or defibrillation for the management of malignant ventricular arrhythmias; and (5) incorporation of multiple pacing facilities in single implantable units.
Collapse
Affiliation(s)
- M A de Belder
- Department of Cardiological Sciences, St George's Hospital Medical School, London, United Kingdom
| | | |
Collapse
|
26
|
Affiliation(s)
- P J Troup
- University of Wisconsin, Milwaukee Clinical Campus
| |
Collapse
|
27
|
Manolis AS, Tan-DeGuzman W, Lee MA, Rastegar H, Haffajee CI, Huang SK, Estes NA. Clinical experience in seventy-seven patients with the automatic implantable cardioverter defibrillator. Am Heart J 1989; 118:445-50. [PMID: 2773768 DOI: 10.1016/0002-8703(89)90256-1] [Citation(s) in RCA: 96] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Seventy-seven patients with drug-refractory sustained ventricular tachycardia (VT) (28 patients) or ventricular fibrillation (VF) (49 patients) underwent implantation of an automatic cardioverter defibrillator (AICD). The 67 men and 10 women, with a mean age of 60 +/- 12 years (range 18 to 79), had coronary artery disease (60 patients), idiopathic cardiomyopathy (eight patients), mitral valve prolapse (four patients), hypertensive heart disease (one patient), Ebstein's anomaly (one patient), long QT syndrome (one patient), and primary electrical disease (two patients). The mean left ventricular ejection fraction was 35 +/- 16% (range 10% to 75%). Sustained VT/VF was induced in 64 patients (83%) at baseline electrophysiologic testing. A mean of 4.1 +/- 1.3 antiarrhythmic drugs failed to control the arrhythmia. Associated surgery at AICD implantation included coronary artery bypass in 19 patients, coronary bypass with aneurysmectomy in six patients, and aneurysmectomy alone in one patient. Five patients had only prophylactic patches implanted during aneurysmectomy or coronary bypass and the AICD device was subsequently implanted under local anesthesia to prevent arrhythmia recurrence or to control persistently inducible VT. Operative mortality was 2.6% with two deaths from intractable VF. Fifty-two patients (69%) continued receiving antiarrhythmic drugs to suppress spontaneous VT. During a mean follow-up of 15 +/- 13 months (range 1 to 63), six patients died: two suddenly due to probable pulse generator failure (greater than 2 years old), one of acute myocardial infarction, two of heart failure, and one of respiratory failure.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- A S Manolis
- Department of Medicine, Tufts University School of Medicine, Boston, MA 02111
| | | | | | | | | | | | | |
Collapse
|
28
|
Abstract
Electrical therapy for tachyarrhythmias attempts to achieve one or more of three aims: a) prevention of tachycardia; (b) control of the hemodynamic effect of tachycardia; (c) termination of tachycardia. In practice, long term control of tachycardia in selected patients can be achieved with implantable devices which can automatically recognize and terminate tachycardias. Termination can be achieved with a number of pacing modalities. These pacing modalities are reviewed in this article and some guidelines to the choice of modality are given. Patients with supraventricular tachycardia are often more appropriately treated with drugs or surgery but some can be effectively treated with antitachycardia pacing. Some patients with ventricular tachycardia can be successfully treated with these devices but this group is at risk of tachycardia acceleration or degeneration in response to pacing. An implantable cardioverter-defibrillator should be used as a backup in these patients. Present generation devices now incorporate antitachycardia pacing, low energy cardioversion, and higher energy defibrillation in the same unit.
Collapse
Affiliation(s)
- M A de Belder
- Department of Cardiological Sciences, St. George's Hospital Medical School, London, England
| | | |
Collapse
|
29
|
Gertsch M, Hottinger S, Mettler D, Leupi F, Gurtner HP. Conversion of induced ventricular tachycardia by single and serial chest thumps: a study in domestic pigs 1 week after experimental myocardial infarction. Am Heart J 1989; 118:248-55. [PMID: 2750646 DOI: 10.1016/0002-8703(89)90182-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
A single chest thump (CT) is widely accepted in the emergency treatment of ventricular asystole, whereas there exists controversy about this method for the interruption of ventricular tachycardia (VT). Hitherto, delivering serial chest thumps (SCTs) has been described only once for the treatment of VT. A systematic analysis for interruption of VT by CT or SCTs (or both) is lacking. We have therefore investigated this subject in five domestic pigs after experimental myocardial infarction. Manual conversion was attempted in 20 induced VTs. Six VTs were converted by CT, seven VTs were converted by the first SCTs, and six VTs were converted by the last of multiple (two to seven) SCTs. The overall success was 95%. There were no serious complications. The rate of successful SCTs exceeded the rate of VT by 10% to 126%. The technique of SCTs, the mechanisms of manual conversion, and the controversial opinions regarding the value of precordial thumping in asystole, VT, and ventricular fibrillation are discussed. SCTs should be practiced only very cautiously in patients until further experience is available.
Collapse
Affiliation(s)
- M Gertsch
- Department of Cardiology, Medical University Clinic, Inselspital Bern, Switzerland
| | | | | | | | | |
Collapse
|
30
|
Kappenberger L, Valin H, Sowton E. Multicenter long-term results of antitachycardia pacing for supraventricular tachycardias. Am J Cardiol 1989; 64:191-3. [PMID: 2662744 DOI: 10.1016/0002-9149(89)90455-4] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
This report describes the multicenter experience of the Tachylog antitachycardia pacemaker (Siemens-Elema) in the treatment of drug-refractory, recurrent supraventricular arrhythmias. The device has been implanted in 63 patients (mean age 47 years). The arrhythmias were atrial tachycardia in 4 patients (6%), atrioventricular nodal reentry tachycardia in 23 patients (37%), circus movement tachycardia via an overt bypass tract in 17 patients (27%) and via a concealed bypass tract in 19 patients (30%). The mean follow-up period was 30 months. In 28 patients (44%) arrhythmia control was achieved with the pacemaker therapy alone. In 31 patients (49%) drug therapy had to be reintroduced to obtain control of recurrent arrhythmias. Four patients (6%) were definite nonresponders. In 4 patients (6%) the pulse generator was explanted either because it was not tolerated or because of tachycardia-sensing failure. No syncope or death was observed during follow-up. Thus, antitachycardia pacing gives satisfactory results in selected patients with drug-refractory supraventricular tachycardias.
Collapse
Affiliation(s)
- L Kappenberger
- Division of Cardiology, University Hospital, Lausanne, Switzerland
| | | | | |
Collapse
|
31
|
Manolis AS, Rastegar H, Payne D, Cleveland R, Estes NA. Surgical therapy for drug-refractory ventricular tachycardia: results with mapping-guided subendocardial resection. J Am Coll Cardiol 1989; 14:199-208. [PMID: 2786895 DOI: 10.1016/0735-1097(89)90073-9] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Surgical therapy with mapping-guided subendocardial resection was used in 30 patients with drug-refractory ventricular tachycardia. Results of preoperative, intraoperative and postoperative electrophysiologic evaluation and long-term clinical follow-up are reported. Left ventricular aneurysm was located in the inferior wall in 8 patients and in the anterior wall in 22. Left ventricular mapping was performed in 15 patients preoperatively and in all 30 patients intraoperatively. Subendocardial resection was supplemented with cryoablation in 26 patients and with laser photocoagulation in 4. Coronary bypass surgery was performed in 27 patients. The surgical mortality rate was 10%; the three deaths were due to cardiogenic shock, pneumonia and sepsis, respectively. At postoperative electrophysiologic study, ventricular tachycardia was inducible in 8 (30%) of 27 patients. Previously ineffective antiarrhythmic drugs were effective in preventing the induction of ventricular tachycardia in four of these eight patients. Two of the remaining four patients received an automatic implantable cardioverterdefibrillator; the other two were treated with amiodarone. At a mean follow-up period of 18 +/- 17 months (range 1 to 52), there has been one sudden death and one nonfatal recurrence of ventricular tachycardia in the 18 patients without inducible arrhythmias postoperatively. Among the eight patients with inducible ventricular tachycardia after subendocardial resection, there has been one nonfatal ventricular tachycardia recurrence. Thus, among the 27 patients surviving surgery, 17 (63%) were cured with surgery alone, and another 7 (26%) had their ventricular tachycardia controlled with drugs (n = 5) or the defibrillator (n = 2). Inability to completely map the tachycardia, a clinical history of cardiac arrest requiring resuscitation and the presence of myocardial infarction within 2 months predicted postoperative arrhythmia inducibility and recurrence.
Collapse
Affiliation(s)
- A S Manolis
- Department of Medicine, Tufts University School of Medicine, New England Medical Center, Boston, Massachusetts 02111
| | | | | | | | | |
Collapse
|
32
|
de Belder MA, Camm AJ. Implantable cardioverter-defibrillators (ICDs) 1989: how close are we to the ideal device? Clin Cardiol 1989; 12:339-45. [PMID: 2736821 DOI: 10.1002/clc.4960120609] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Major technical advances over the last few years have led to significant improvements in implantable cardioverter-defibrillators. Tachycardias can be detected using a number of criteria which include rate, rate of onset, duration, and stability of tachycardia. A number of target tachyarrhythmias can be distinguished in the same patient and differentiated from sinus or other benign tachycardias. Different tachycardias can then be treated with different electrical therapies. Therapies now incorporated in the latest generation of implantable devices include comprehensive antitachycardia pacing techniques, low-energy cardioversion and high-energy cardioversion-defibrillation. Bradycardia support pacing is also incorporated. Improvements in the electrodes used for sensing tachycardia and delivering therapy have resulted in the first implants of devices without the need for thoracotomy. Improvements in capacitor technology have resulted in a gradual reduction in the size of devices in spite of their increasing sophistication. Further research is needed to evaluate different shock charges and waveforms. Tachycardia prevention by implanted devices is also a field of much current research. Thus, though not yet "ideal," the latest generation of implantable cardioverter-defibrillators represents an important therapeutic option in the treatment of ventricular tachyarrhythmias.
Collapse
Affiliation(s)
- M A de Belder
- Department of Cardiological Sciences, St. George's Hospital Medical School, London, England
| | | |
Collapse
|
33
|
Epstein AE, Kay GN, Plumb VJ, Shepard RB, Kirklin JK. Combined automatic implantable cardioverter-defibrillator and pacemaker systems: implantation techniques and follow-up. J Am Coll Cardiol 1989; 13:121-31. [PMID: 2909559 DOI: 10.1016/0735-1097(89)90559-7] [Citation(s) in RCA: 58] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The automatic implantable cardioverter-defibrillator (AICD) effectively prevents death due to ventricular tachycardia or ventricular fibrillation. Some patients who need an AICD also require cardiac pacing to treat symptomatic bradycardia, bradycardia after defibrillation, or to provide a rate floor to reduce the frequency of bradycardia-related ventricular arrhythmias. Some patients also can benefit from antitachycardia pacing. A mapping technique to implant a pacemaker and AICD sensing leads is presented. For patients with a pacemaker who later need an AICD, the left ventricle is mapped with use of the AICD rate-sensing electrodes to identify a site at which the minimal pacemaker stimulus and maximal ventricular electrogram amplitudes are recorded. An external cardioverter-defibrillator that has amplifiers similar to those in the AICD is used to monitor the rate-sensing electrogram. For patients with an implanted AICD, pacemaker implantation is undertaken by mapping the right ventricle with the pacemaker lead while the AICD is in standby mode; the AICD beep monitor is then used to determine a site where pacemaker stimulus detection by the AICD does not occur. Eight patients underwent implantation of a combined AICD-pacemaker system (four ventricular antitachycardia pacemakers, three ventricular demand pacemakers and one atrial demand pacemaker). Neither inhibition of AICD arrhythmia detection nor double counting occurred. Satisfactory AICD-pacemaker function was shown in all patients postoperatively, and no pacemaker malfunction was observed. Thus, with currently available technology, a combined AICD-pacemaker system can be implanted with satisfactory function of both devices and without adverse device-device interactions.
Collapse
Affiliation(s)
- A E Epstein
- Department of Medicine, University of Alabama, Birmingham 35294
| | | | | | | | | |
Collapse
|
34
|
Abstract
During the course of a seven year implant experience with the Automatic Implantable Cardioverter-Defibrillator (AICD) now extending to well over 3,700 implantees, several functional advances have been made in the pulse generators, and criteria for implantation were successively broadened. Survival statistics have been excellent with 1-year arrhythmic survival over 98%, and total survival from all causes of death in excess of 60% at 5 years. Still, only relatively few of the patients who could possibly be helped by this device actually receive one. Reasons for this are probably complex but include, among other things, the relative newness of electrophysiology as a subspecialty, and a lack of appreciation by the general medical public in regard to this particular treatment modality. Small increases in referral patterns thus can have the potential to produce marked increases in the utilization of AICDs. Additionally, other high risk populations appear to be ready for inclusion into AICD therapeutic trials, and techniques also appear at hand to examine presumably healthy populations so as to predict those subject to suffer eventual sudden cardiac arrest. Under such circumstances, the ultimate impact of AICD therapy can hardly be imagined.
Collapse
Affiliation(s)
- M M Mower
- Sinai Hospital of Baltimore, Inc., Maryland 21215
| | | |
Collapse
|
35
|
Fisher JD, Johnston DR, Furman S, Mercando AD, Kim SG. Long-term efficacy of antitachycardia pacing for supraventricular and ventricular tachycardias. Am J Cardiol 1987; 60:1311-6. [PMID: 3687782 DOI: 10.1016/0002-9149(87)90613-8] [Citation(s) in RCA: 60] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Over a 14-year period, 53 patients received implanted pacemakers to assist in the control of recurrent tachycardias. Indications were: prevention of tachycardia in 2 patients with supraventricular tachycardia (SVT), and 4 with ventricular tachycardia (VT); termination of tachycardia (15 SVT, 20 VT); and long-term periodic programmed electrical stimulation with potential for tachycardia termination (12 VT). Pacemakers for prevention of VT were implanted in 3 patients with prolonged QT interval syndromes and 1 in whom Holter monitoring showed a significant reduction in ectopic activity during pacing. Pacers were implanted for tachycardia termination only after patients underwent a rigorous protocol aimed at achieving 100 trials of the proposed modality. Patients with tachycardia also requiring antibradycardia pacemakers received pacemakers capable of noninvasive programmed stimulation for use during follow-up. There were no tachycardia recurrences among those patients in whom pacemakers were implanted for prevention. Pacers capable of outpatient programmed stimulation were useful, and it may be desirable to expand their use. The 15 patients with pacers designed for termination of SVT were followed for a mean of 68 months. Among these, actuarial continuation of pacing efficacy was 93% at 1 year, and 78% at 5 years. The 20 patients with pacers for termination of VT were followed for a mean of 37 months. Actuarial efficacy was 78% at 1 year, and 55% at 5 years. Sudden death occurred in 4 of these patients, none clearly pacer related. Pacemakers can play a major therapeutic role in some patients with recurrent tachycardias. The role of such pacemakers in patients with VT may be expanded with the advent of combined pacer-defibrillators.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- J D Fisher
- Division of Cardiology (Arrhythmia Service), Montefiore Medical Center, Bronx, New York
| | | | | | | | | |
Collapse
|